News

Regenerative medicine was widely discussed at CCC 2012, and Heart Institute researchers continue to innovate in harnessing the body’s own stem cells to fix or replace damaged cardiac tissue. Two Heart Institute graduate students presented research nominated for the Trainee Research Award in basic

Patients who have a heart attack followed by return of spontaneous circulation (ROSC), but not consciousness, have a poor prognosis. The neurological outcomes for these so-called ROSC patients can be aided by rapid cooling of the body (therapeutic hypothermia) in the cardiac catheterization lab, but

Patients placed on a heart-lung machine for heart surgery have a high incidence of neurocognitive deficits, including memory loss, attention deficits and decline in motor skills. New data from Heart Institute investigators provide some reassurance, though, that many of these deficits resolve over

Within 30 days of non-cardiac surgery, one in 10 patients will have a major vascular complication. In the CCC State-of-the-Art lecture, Dr. PJ Devereux of McMaster University brought to the fore work being done to reduce myocardial injury after non-cardiac surgery (MINS). Surgery is stressful, and

Imaging, such as positron emission tomography (PET) and echocardiography, is vital for diagnosing heart disease, but it can also be used in new ways to assess the progress of disease or treatment. Tracking the Impact of Diabetes with PET James Haley, a master’s candidate at the Heart Institute

Several Heart Institute staff members were the recipients of significant honours at this year’s congress. Foremost of these were Dr. Robert Roberts, Heart Institute President and CEO, and Dr. Lyall Higginson. A Pioneering Researcher Dr. Roberts received the Canadian Cardiovascular Society’s Research

The Heart Institute’s landmark RAFT trial, released in 2010, showed that cardiac resynchronization therapy (CRT) in combination with an implantable cardioverter defibrillator (ICD) device reduces the risk death by 24 per cent in patients with mild to moderate heart failure. Two new studies mined

An Overview from the Cardiovascular Perspective Diabetes is a large and growing problem in Canada, with diabetic patients at much greater risk for dangerous cardiovascular events, including recurrent heart attacks and the development of heart failure. Because it’s such a major contributor to heart

Once again, the University of Ottawa Heart Institute had more than 40 clinical and research presentations on the program at the annual American Heart Association Scientific Sessions. These, along with other major developments in the world of cardiovascular medicine, made for a lively conference. New

Some of the biggest news to come out of AHA this year was the results from preliminary clinical trials of two new LDL cholesterol-lowering drugs that show a substantial decrease in LDL levels well below the reductions seen with statins or ezetimibe alone. The new drugs belong to a class called PCSK9